Silver Book Fact

A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s disease and $12,294/QALY for patients with advanced disease.

Hoerger, Thomas J., Mohan V. Bala, Clayton Rowland, Marianne Greer, Elizabeth A. Chrischilles, and Robert G. Holloway. Cost Effectiveness of Pramipexole in Parkinsonâ??s Disease in the U.S. Pharmacoeconomics. 1998; 14(5): 541-57. http://www.ncbi.nlm.nih.gov/pubmed/10344917

Reference

Title
Cost Effectiveness of Pramipexole in Parkinsonâ??s Disease in the U.S.
Publication
Pharmacoeconomics
Publication Date
1998
Authors
Hoerger, Thomas J., Mohan V. Bala, Clayton Rowland, Marianne Greer, Elizabeth A. Chrischilles, and Robert G. Holloway
Volume & Issue
Volume 14, Issue 5
Pages
541-57
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Medicines Allow Patients to Remain Independent Longer: New Alzheimer’s medicine delays need for costly home care  
  • Deep brain stimulation, an electrical signal delivered deep inside the brain, provides significant symptomatic relief for Parkinson’s patients whose medication is no longer effective.  
  • A study of rasagiline mesylate in Parkinson’s disease patients showed improved motor fluctuations and other Parkinson’s disease symptoms.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 Medicare costs for people with the disease would be…  
  • Willena is 75 and was diagnosed with Alzheimer’s disease five years ago Her daughter and primary caregiver, Wanda
    “Willena is 75 and was diagnosed with Alzheimer’s disease five years ago. Her daughter and primary caregiver, Wanda Richardson, believes that her mother went undiagnosed for at least 15 years…